Umoja Biopharma

Umoja Biopharma

Develops in vivo CAR T-cell therapies

About Umoja Biopharma

Simplify's Rating
Why Umoja Biopharma is rated
A+
Rated A on Competitive Edge
Rated A+ on Growth Potential
Rated A on Differentiation

Industries

Biotechnology

Healthcare

Company Size

51-200

Company Stage

Series C

Total Funding

$363M

Headquarters

Seattle, Washington

Founded

2019

Overview

Umoja Biopharma focuses on immunotherapy by reprogramming T cells in the body to target and destroy cancer cells. Unlike traditional methods that modify cells outside the body, Umoja's approach modifies the immune system in vivo, aiming for lasting remissions. The company primarily targets patients with solid tumors and hematological cancers that have not responded to existing treatments. Its business model is based on developing and commercializing a proprietary CAR T-cell gene therapy platform that is scalable and can treat cancers at various stages. By producing off-the-shelf therapies in-house, Umoja can distribute its treatments more efficiently than those requiring individual customization. The goal is to leverage the immune system's power to improve cancer treatment outcomes.

Simplify Jobs

Simplify's Take

What believers are saying

  • Raised $100M in Series C to advance in vivo CAR T pipeline.
  • Collaborated with Nona Biosciences to enhance CAR-T cell therapy development.
  • Scott Myers' appointment as Chairman brings experienced leadership for growth.

What critics are saying

  • Competition from Interius BioTherapeutics expanding in vivo trials to Europe.
  • AI-driven protein design advancements by competitors like Archon Biosciences.
  • High investor expectations from oversubscribed Series C financing.

What makes Umoja Biopharma unique

  • Umoja Biopharma reprograms T cells in vivo, unlike traditional ex vivo methods.
  • Their CAR T-cell platform is scalable, treating cancers at all stages.
  • Umoja's off-the-shelf therapies offer efficient production and distribution.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$363M

Above

Industry Average

Funded Over

3 Rounds

Notable Investors:
Series C funding is usually for startups that are doing well and are looking for more money to fuel major growth, such as acquiring other companies, expanding into global markets, or launching new product lines. Investors typically include larger venture capital firms and private equity.
Series C Funding Comparison
Above Average

Industry standards

$50M
$50M
Medium
$62M
SeatGeek
$100M
Oura
$100M
Umoja Biopharma

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Unlimited Paid Time Off

Commuter Benefits

Phone/Internet Stipend

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

0%

2 year growth

2%
GeekWire
Mar 18th, 2025
Geekwire Awards: Health Innovation Of The Year Field Is Dominated By Finalists Battling Cancer

The 2025 GeekWire Award finalists for Health Innovation of the Year are dominated by ventures that aim to outwit cancer with groundbreaking new technologies. The contenders range from a newly formed startup to a leading U.S. cancer institute and companies in between. Joining the cohort is a business with technology to help healthcare providers better manage appointments and access to providers.This awards category recognizes pioneering health, life science, biotechnology or medical breakthroughs that hold great promise for improving peoples’ lives and enhancing the healthcare system.The finalists are Archon Biosciences, DexCare, Fred Hutch Cancer Center, Talus Bioscience and Umoja Biopharma.Last year’s winner was CalmWave, a Seattle health-tech startup that created a system for making sense of the alarms triggered by the devices that monitor hospital ICU patients.Continue reading for details on each of this year’s finalists, and vote here or below.Archon BiosciencesArchon Biosciences emerged from stealth last October with $20 million in funding. The Seattle biotech company is running with technology developed in the lab of University of Washington biochemist and Nobel Prize winner David Baker.Archon’s proprietary protein structures, known as Antibody Cages or AbCs, combine two biomedical tools — naturally occurring antibodies and custom-designed proteins — to create a single new protein structure. These protein structures, or AbCs, are optimized with the aid of generative AI to travel in the body in controllable ways and engage with target cells in a more specific manner.“What we like to say is, it’s not whether you’re given a drug, it’s how you’re given it,” said CEO and co-founder James Lazarovits

GeekWire
Mar 4th, 2025
Tech Moves: Starbucks Names Cfo; Avanade Bolsters C-Suite; Tune Therapeutics Gets Ceo

Tech Moves covers notable hires, promotions and personnel changes in the Pacific NW tech community. Submissions: [email protected] Smith, CFO of Starbucks. (LinkedIn Photo)— Starbucks announced Cathy Smith as its chief financial officer. Smith was most recently at Nordstrom for two years, and has held CFO roles at Bright Health, Target, Express Scripts, Walmart and others. Her longest role was at the defense and space juggernaut Raytheon.Smith succeeds Rachel Ruggeri, who was at Starbucks for more than two decades, ascending to the CFO role in 2021.The coffee giant announced layoffs of 1,100 corporate employees, including 612 in Seattle. It marks one of Starbucks’ largest layoffs and comes as CEO Brian Niccol turns to tech to help turn around the slumping business after taking over in September.— Avanade, a Seattle-based tech consulting and services company, announced a slate of C-suite hires

Benzinga
Jan 14th, 2025
Umoja Biopharma Raises $100M Series C

Umoja Biopharma announced a $100 million Series C financing to advance its in vivo CAR T cell therapy pipeline. The round was co-led by Double Point Ventures and DCVC Bio, with participation from investors like ARK Invest and SoftBank Vision Fund 2. The funds will support clinical development, including the lead CD22 UB-VV400 program. Campbell Murray, M.D., joins the Board of Directors. This financing highlights Umoja's potential to innovate in oncology and autoimmune treatments.

The Manila Times
Jan 14th, 2025
Umoja Biopharma Announces Oversubscribed $100 Million Series C Financing to Advance In Vivo CAR T Pipeline through Key Oncology Clinical Milestones

Umoja Biopharma announces oversubscribed $100 million Series C financing to advance in vivo CAR T pipeline through key oncology clinical milestones.

The Pharma Letter
Jan 14th, 2025
Umoja Biopharma closes $100 million financing

Seattle, USA- based clinical-stage CART-T therapies developer Umoja Biopharma, today announced the closing of a $100 million Series C financing.

Recently Posted Jobs

Sign up to get curated job recommendations

Umoja Biopharma is Hiring for 3 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update Umoja Biopharma's jobs every few hours, so check again soon! Browse all jobs →